Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors

Summary

The purpose of this phase II trial is to evaluate the safety and efficacy of belzutifan (MK-6482) in patients with advanced pheochromocytoma/ paraganglioma (PPGL) or pancreatic neuroendocrine tumors (pNET).

General Information

NCT#: NCT04924075
Study ID: 6482-015
Trial Phase: Phase II

Trial Sponsor: Merck Sharp & Dohme Corp.
Therapies Used in This Trial: Belzutifan

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search